To cure myeloma by fostering research, education and excellence in clinical care worldwide.

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this workshop is for you!

This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

 Preliminary Agenda

The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient population. Given the plethora of different drug products in this space, including antibody-drug conjugates, T cell engagers and CAR T cells, this is a busy landscape and requires specific education around patient characteristics, treatment selection, and toxicity management to provide the best treatment options for our patients.

At the conclusion of this educational activity, you will be able to:
1. Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.
2. Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.
3. Understand toxicities and their management post-novel immune strategies.

IMS is proud to announce the new webIMarS series, where with the leadership of local hematology groups, we will co-host a series of 90-minute webinars on Relapsed Refractory Multiple Myeloma around the globe.

Join our colleagues with the Mumbai Hematology Group, on Sunday, October 20 beginning at 11:30 am India Standard Time.

Program

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.

IMS is pleased to announce that the 6th Annual Immune Effector Cell Therapies in Multiple Myeloma Workshop will take place from March 28-29, 2025 in Boston, MA.

More details will be available soon! 

Join us for a dynamic educational workshop on the diagnosis, treatment, and monitoring of plasma cell malignancies, including current practices and opportunities for improvement. This workshop will include lectures plus roundtable discussions around hot and controversial topics, featuring point-counterpoint conversations between invited speakers and local hematologists based on both challenging questions and clinical cases.